Susan L. Slager, PhD, discusses the background of her research on inherited germline genetics for risk of chronic lymphocytic ...

STC-15, an investigational RNA methyltransferase inhibitor, has shown promising clinical activity and an encouraging safety ...

The FDA has granted LBL-024 orphan drug designation (ODD) for the treatment of neuroendocrine cancer. The agent has already ...

The FDA has received a biologics license application submission for RP1 plus nivolumab in patients with PD-1 ...

Samer A. Al’Hadidi, MD, discusses factors influencing early use of chimeric antigen receptor T-cell therapy in patients with ...

The phase 3 SKYSCRAPER-01 trial of tiragolumab and atezolizumab in PD-L1-high non–small cell lung cancer did not meet its primary end point of overall survival.

Alexander J. Fife, MD, discussed the challenges of diagnosing endometrial cancer, highlighting delays in care.

Along with the Oncology Brothers, Paolo Tarantino, MD, discusses the post -hoc subgroup analysis from the EMERALD study ...

Along with the Oncology Brothers, Paolo Tarantino, MD, shares insights on what has been learned about proactive monitoring ...

Along with the Oncology Brothers, Paolo Tarantino, MD, elaborates on the San Antonio Breast Cancer Symposium (SABCS) 2022 ...

Chunhui Han, PhD, discusses the potential feasibility of the integration of Gallium 68 PSMA-11 in biology-guided radiotherapy ...

Along with the Oncology Brothers, Paolo Tarantino, MD, discusses ongoing studies investigating novel uses of oral selective ...